Aulmann S, Adler N, Rom J, Helmchen B, Schirmacher P, Sinn H P
Department of Pathology, University of Heidelberg, Heidelberg, Germany.
J Clin Pathol. 2006 Apr;59(4):424-8. doi: 10.1136/jcp.2005.029264. Epub 2006 Feb 23.
To evaluate the role of c-myc oncogene amplifications in the progression of invasive breast carcinomas.
c-myc gene copy number was evaluated in a series of 49 primary breast carcinomas and the corresponding local recurrences using fluorescence in situ hybridisation.
11 of the primary carcinomas (22%) harboured c-myc amplifications; these tumours typically were hormone receptor negative and occurred in younger patients (43 v 53 years). At the time of relapse, six additional tumours had acquired a c-myc amplification. The mean recurrence-free survival was 24 months; c-myc amplified tumours relapsed significantly earlier than carcinomas without amplification (18 v 27 months). Univariate analysis showed a worse overall survival in these patients.
While c-myc amplifications can be observed in early stage breast cancer, especially in younger patients, they often occur later in tumour development and appear to be associated with disease progression.
评估c-myc癌基因扩增在浸润性乳腺癌进展中的作用。
采用荧光原位杂交技术对49例原发性乳腺癌及其相应局部复发灶进行c-myc基因拷贝数评估。
11例原发性癌（22%）存在c-myc扩增；这些肿瘤通常为激素受体阴性，且发生于较年轻患者（43岁对53岁）。复发时，另外6例肿瘤出现了c-myc扩增。无复发生存期的均值为24个月；c-myc扩增的肿瘤比未扩增的癌复发明显更早（18个月对27个月）。单因素分析显示这些患者的总生存期较差。
虽然在早期乳腺癌中可观察到c-myc扩增，尤其是在较年轻患者中，但它们常在肿瘤发展后期出现，且似乎与疾病进展相关。
